Mabwell - Salamanca Free Press

Press Releases

Mabwell Releases 6 Study Results of Innovative Drugs and Platforms at the 2025 AACR Annual Meeting

Mabwell

April 30, 2025

SHANGHAI , April 30, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, presented 6 ...

Press Releases

Mabwell Announces NMPA Approval to Initiate Clinical Trial of novel B7-H3-targeting ADC for Advanced Solid Tumors in Combination with PD-1 Inhibitor

Mabwell

April 2, 2025

SHANGHAI , April 2, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its novel ...

Press Releases

Mabwell’s Nectin-4 Targeted ADC 9MW2821 Combination Therapy Demonstrates 87.5% ORR and Granted CDE Breakthrough Therapy Designation

Mabwell

January 9, 2025

SHANGHAI , Jan. 9, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced a significa...

Press Releases

Mabwell’s Novel Nectin-4 Targeting ADC 9MW2821 Approved for 2 Clinical Trials by CDE of NMPA

Mabwell

November 14, 2024

SHANGHAI , Nov. 14, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its n...

Salamanca Press

Get in touch with The Salamanca Press

Submit Content

Advertise

Subscribe